(Clobetasol propionate + salicylic acid + tretinoin + urea) is under clinical development by Gen Ilac ve Saglik Urunleri and currently in Phase II for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase II drugs for Plaque Psoriasis (Psoriasis Vulgaris) have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Clobetasol propionate + salicylic acid + tretinoin + urea)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Clobetasol propionate + salicylic acid + tretinoin + urea) overview
GN-037, a combination of clobetasol 17-propionate, salicylic acid, retinoic acid and urea is under development for the treatment of mild to moderate plaque psoriasis. The therapeutic candidate is administered through topical route in the form of cream. Clobetasol 17-propionate acts by targeting glucocorticoid receptor.
See Also:
Gen Ilac ve Saglik Urunleri overview
Gen Ilac ve Saglik Urunleri (Gen Ilac ve) is a specialty pharmaceutical company to bring innovative therapies and rare solutions to our community. The company is headquartered in Ankara, Turkey.
For a complete picture of (Clobetasol propionate + salicylic acid + tretinoin + urea)’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
